

Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiffs
Sepracor Inc. and
University of Massachusetts*

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

SEPRACOR INC., et al.,))
))
Plaintiffs,)	Civil Action No. 07-CV-4213 (MLC)
))
v.)	(Filed Electronically)
))
SUN PHARMACEUTICAL INDUSTRIES))
LTD., et al.,))
))
Defendants.))
))

STIPULATION AND ORDER

The Court, upon the consent and request of Plaintiffs Sepracor Inc. and University of Massachusetts (collectively, "Sepracor") and Defendants GeoPharma, Inc. and Belcher Pharmaceuticals, Inc. (collectively, "GeoPharma"), hereby acknowledges the following Stipulation and issues the following Order.

STIPULATION

1. This Court has subject matter jurisdiction over this patent infringement action (the "Action"). Sepracor and GeoPharma consent to personal jurisdiction in this Court for purposes of the Action. For purposes of the Action, GeoPharma does not contest personal jurisdiction or venue.

2. In this Action, Sepracor has charged GeoPharma with infringement of United States Patent Nos. 7,214,683 ("the '683 patent") and 7,214,684 ("the '684 patent") in connection with GeoPharma's submission of Abbreviated New Drug Application ("ANDA") No. 78-355 directed to generic tablets containing 5 milligrams of desloratadine per tablet to the U.S. Food and Drug Administration ("FDA").

3. In response to Sepracor's charges of patent infringement, GeoPharma has alleged certain defenses, including that the '683 patent and the '684 patent are invalid and not infringed by the generic tablet product containing 5 milligrams of desloratadine per tablet that is the subject of ANDA No. 78-355. No decision has been obtained by either party from this Court regarding these charges of infringement or these defenses.

4. GeoPharma has not rebutted the statutory presumption that the '683 patent and the '684 patent are valid and enforceable in this Action. This admission is without prejudice to GeoPharma's defenses and counterclaims that the '683 patent and the '684 patent are invalid.

5. GeoPharma admits that the submission of ANDA No. 78-355 to FDA for the purpose of obtaining regulatory approval to engage in the commercial manufacture, use and/or sale of generic tablets containing 5 milligrams of desloratadine per tablet within the United States before the expiration of the '683 patent and the '684 patent was a technical act of infringement of those patents under 35 U.S.C. § 271(e)(2)(A). This admission is without prejudice to GeoPharma's defenses and counterclaims that the '683 patent and the '684 patent are invalid and/or that the product described by ANDA No. 78-355 does not infringe either patent.

6. GeoPharma has agreed that each of the defenses set forth in GeoPharma's Answer, Defenses and Counterclaims, including the allegations and averments contained therein, should be dismissed, without prejudice.

7. Sepracor and GeoPharma make the following releases: (a) GeoPharma hereby releases and discharges Sepracor and its respective Affiliates, successors, assigns, directors, officers, employees, agents and customers from all causes of action, demands, claims,

damages and liabilities of any nature, whether known or unknown, arising from or in connection with this Action, or the '683 Patent and/or the '684 Patent, including, without limitation, all claims that GeoPharma has asserted or could have asserted in this Action; (b) Sepracor hereby releases and discharges GeoPharma and its Affiliates, successors, assigns, directors, officers, employees, agents and customers from all causes of action, demands, claims, damages and liabilities of any nature, whether known or unknown, arising from or in connection with this Action, or the '683 Patent and/or '684 Patent, including, without limitation, all claims that Sepracor has asserted or could have asserted in this Action; and (c) neither Sepracor or GeoPharma, nor any of their Affiliates or agents shall institute any new litigation with respect to the '683 Patent, the '684 Patent, U.S. Patent Nos. 7,211,582; 5,731,319; and 5,595,997, and any other patents owned by Sepracor or its Affiliates that would be infringed by the manufacture, having manufactured, and/or marketing of any Generic Desloratadine Product, including any continuations, continuations-in-part, divisionals, reissues or reexaminations thereof (collectively the "Desloratadine Patents") against any product covered by ANDA No. 78-355 or any GeoPharma ANDA covering any plain (*i.e.*, not rapidly dissolving) tablet product that contains desloratadine as the sole active ingredient and that is approved for marketing in the United States of America (collectively the "Generic Desloratadine Products"). Notwithstanding any of the above, nothing in this Stipulation shall prevent Sepracor or GeoPharma from instituting litigation against the other party involving a product other than a Generic Desloratadine Product, in which event nothing in this Stipulation shall prevent: (a) Sepracor from asserting in such litigation that such other product or products infringe any of the Desloratadine Patents or other patents, or (b) GeoPharma from asserting in such litigation that any of the Desloratadine Patents or other patents are not infringed, invalid and unenforceable.

ORDER

Accordingly, pursuant to the above Stipulation, and upon the consent and request of Sepracor and GeoPharma, **IT IS HEREBY ORDERED, ADJUDGED AND DECREED THAT:**

1. The filing of ANDA No. 78-355 was a technical act of infringement of the ‘683 patent and the ‘684 patent under 35 U.S.C. § 271(e)(2)(A). No decision of the Court has been obtained by either party regarding the presumptive validity of the ‘683 patent and the ‘684 patent and/or whether the product described by ANDA No. 78-355 infringes either patent.

2. GeoPharma’s defenses with respect to the ‘683 patent and the ‘684 patent are hereby dismissed, without prejudice.

3. GeoPharma, its officers, agents, servants, employees and attorneys, and those persons in active concert or participation with them who receive actual notice of this Order by personal service or otherwise, are hereby enjoined from manufacturing, using, offering to sell or selling within the United States, or importing into the United States, the generic tablet product containing 5 milligrams of desloratadine per tablet that is the subject of ANDA No. 78-355 during the life of the ‘683 patent and the ‘684 patent, including any extensions and pediatric exclusivities, except pursuant to a license and/or sublicense agreement, as applicable, or other authorization by Sepracor, unless all of the claims of the ‘683 patent and the ‘684 patent are found invalid or unenforceable by a court decision from which no appeal has been or can be taken, other than a petition for a writ of certiorari to the U.S. Supreme Court.


4. Sepracor and GeoPharma each expressly waives any right to appeal or otherwise move for relief from this Stipulation And Order.

5. This Court retains jurisdiction over Sepracor and GeoPharma for purposes of enforcing this Stipulation And Order.

6. This Stipulation And Order shall finally resolve this Action between Sepracor and GeoPharma. Each party shall bear its own fees and costs in connection with this Action, including attorney fees.

7. The Clerk of the Court is directed to enter this Stipulation And Order forthwith.


SEPRACOR INC. and
UNIVERSITY OF MASSACHUSETTS


Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza
Newark, New Jersey 07102-5490
(973) 286-6700

Dominick A. Conde
William E. Solander
FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112
(212) 218-2100

Counsel for Plaintiffs
Sepracor Inc. and University of Massachusetts

GEOPHARMA, INC. and BELCHER
PHARMACEUTICALS, INC.



Jeffrey A. Cohen, Esquire
FLASTER/GREENBERG P.C.
Commerce Center
1810 Chapel Avenue West
Cherry Hill, NJ 08002
(856) 661-1900

Liane M. Peterson
FOLEY & LARDNER LLP
3000 K Street, N.W., Suite 500
Washington, D.C. 20007
(202) 672-5300

Counsel for Defendants
GeoPharma, Inc. and Belcher
Pharmaceuticals, Inc.

SO ORDERED:

This 13th day of Feb, 2009


HONORABLE MARY L. COOPER
UNITED STATES DISTRICT JUDGE